Related Experiment Videos
Selegiline hydrochloride and cognition.
1Department of Neurology, Middlesex Hospital, London, UK.
Acta Neurologica Scandinavica. Supplementum
|January 1, 1991
Summary
Selegiline HCl, at 10 mg daily, enhances attention and memory in Parkinson's and early Alzheimer's disease. It also improves motor function and mood, particularly depression with psychomotor retardation.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Parkinson's disease (PD) and early Alzheimer's disease (AD) are neurodegenerative disorders impacting cognition and motor function.
- Selegiline hydrochloride (HCl) is a selective monoamine oxidase B inhibitor with potential therapeutic effects.
Purpose of the Study:
- To evaluate the efficacy of Selegiline HCl in improving cognitive and motor functions in PD and early AD.
- To assess the impact of Selegiline HCl on mood and subjective well-being.
Main Methods:
- Administration of Selegiline HCl at doses of 10-40 mg per day.
- Assessment of attention, episodic memory, and motor reaction times.
- Evaluation of mood, including depression, anxiety, vitality, euphoria, and energy levels.
Main Results:
- Selegiline HCl (10 mg/day) improved attention and episodic memory in PD and early AD.
- The drug enhanced motor reaction times in PD patients.
- Doses between 10-40 mg/day improved depression, especially in cases with psychomotor retardation and minimal anxiety.
Conclusions:
- Selegiline HCl demonstrates therapeutic potential for cognitive and motor deficits in PD and early AD.
- It may serve as an effective treatment for specific subtypes of depression associated with neurodegenerative conditions.